Scan to get started on Sahi
Rethink Trading
A new age Broking platform with in-house Sahi charts, real-time AI intelligence, and flat ₹10 per order brokerage.
4.5 ★ . 38K+ Ratings Google Play and App Store | IFTA Startup of the year 2025 | Forbes Asia Top 100 Startups to Watch 2026 | 8M+ downloads
Built for single-screen high performance acrossOptions Buying
Options Buying
Options Buying
Introducing the new & improved Sahi Scalper 2.0
Analyse & execute on a multi-chart layout. Watch the Index and Option Charts, Call & Put, Option Chain, simultaneously without moving an eye from your P&L.
Seamless Options Trading with Powerful Tools
Stay nimble and execute faster than ever before – no matter the screen size.
Trade from Charts, at Sahi Speed
Sahi’s powerful charts are built in-house & give you full control over your trades. Manage risk, optimize entries and exits, and never miss a movement – all without leaving your chart.
Real-Time market intelligence with Sahi AI
Tracks trends, identifies breakouts, highlights the hottest stocks
Analyse, Trade Option Strategies With Confidence
Create strategies that work for you. More control, better results.
Personalized Trading:
Tailor Your Space and Strategy
Personalize your homepage layout to match your trading style. Set up your workspace the way you want it, with just the tools you need.
High Performance Trading
at Incredible Value
Pay only ₹10 per executed order.
Latest news
Dr Lal PathLabs Reports Q2 Consolidated Net Profit Of ₹1.9 Billion
Dr. Lal PathLabs posted Q2 consolidated net profit of ₹192 crore compared to ₹151 crore a year earlier. Operating revenue rose to ₹874 crore on the back of 13.6% sample volume growth. Operating EBITDA stood at ₹280 crore with margins at 32.1%, alongside an interim dividend of ₹5 per share.
Marksans Pharma Q2 Consolidated Net Profit Rises To ₹1.41B From ₹983M YoY
Marksans Pharma delivered a strong Q2 FY27 performance as consolidated net profit surged to ₹141 crore from ₹98.3 crore YoY. Operating revenue expanded 30.5% YoY to ₹940 crore, while EBITDA surged 48.3% to a record ₹214 crore with operating margin expanding by 274 bps to 22.8%.
JTEKT India Reports Q2 Standalone Net Profit Of ₹17.5 Crore Vs ₹18.2 Crore YoY
JTEKT India registered a Q2 standalone net profit of ₹17.50 crore, compared to ₹18.20 crore in Q2 FY26. The performance reflects a marginal year-on-year contraction of ~3.85% in standalone earnings.
